BeyondSpring (BYSI) Cash from Investing Activities (2016 - 2026)
BeyondSpring (BYSI) posted Cash from Investing Activities of $4.5 million for Q1 2026, up 187.02% sequentially from -$5.1 million in Q4 2025, and down 28.95% YoY from $6.3 million in Q1 2025.
BeyondSpring (BYSI) Cash from Investing Activities (2016 - 2026) Analysis & Trends
BeyondSpring has reported Cash from Investing Activities for 9 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 28.95% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 257.01% YoY) and the FY2025 annual result came in at $10.8 million, up 189.8% from the prior year.
- Cash from Investing Activities advanced to $4.5 million in Q1 2026 per BYSI's latest filing, from -$5.1 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $10.8 million in Q2 2025 and troughed at -$9.8 million in Q4 2024.
- A 3-year average of $464857.1 and a median of -$1.2 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 47.56% in 2025, then fell 28.95% in 2026.
- Over 3 years, Cash from Investing Activities stood at -$9.8 million in 2024, then jumped by 47.56% to -$5.1 million in 2025, then jumped by 187.02% to $4.5 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $4.5 million, -$5.1 million, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,000.00 |
| Jun 30, 2026 | -5,000.00 |
| Mar 31, 2026 | 4.48 Mn |
| Mar 31, 2026 | 4.48 Mn |
| Dec 31, 2025 | -5.15 Mn |
| Dec 31, 2025 | -5.15 Mn |
| Sep 30, 2025 | -1.22 Mn |
| Sep 30, 2025 | -1.22 Mn |
| Jun 30, 2025 | 10.85 Mn |
| Jun 30, 2025 | 10.85 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Dec 31, 2024 | -9.82 Mn |
| Dec 31, 2024 | -9.82 Mn |
| Sep 30, 2024 | -2.20 Mn |
| Sep 30, 2024 | -2.20 Mn |
| Dec 31, 2021 | -4.73 Mn |
| Dec 31, 2021 | -4.73 Mn |
| Sep 30, 2021 | 9.34 Mn |
| Sep 30, 2021 | 9.34 Mn |